HKSE:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:27 UTC

Last close

n/aHKD

Market data

82.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
21.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
12.6%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
20.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.27Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.12 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.96x

-0.59x

-1.22x

1.31x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.96x
Its own average over 6 years, 703.0M.
Profit-0.59x
Its own average over 6 years, -292.0M.
Free cash flow-1.22x
Its own average over 6 years, -231.1M.
Debt1.31x
Its own average over 6 years, 444.6M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at -1.22 times.

Sales is 1.96 times its own 6-year average; Profit is -0.59 times its own 6-year average; Free cash flow is -1.22 times its own 6-year average; Debt is 1.31 times its own 6-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 6-year average1.96
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit against its own 6-year average-0.59
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Free cash flow against its own 6-year average-1.22
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Debt against its own 6-year average1.31
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
HKD